ClinicalTrials.gg
Not yet recruitingNCT07949097RASSUREUpdated Nov 19, 2026

RASSURE - Virtual Reality to Soothe, Secure, Simulate Uses, and Successfully Complete the Examination

An interventional study of Traditional care habituation programme and Embrace Plus wristband in Psychological Disability and Mental Disability, sponsored by Pôle Saint Hélier. Not yet recruiting at 2 sites in France. Open to participants aged 9 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Pôle Saint Hélier · Not applicable, Interventional, and Health services research

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Study summary

The RASSURE study aims to evaluate the effect of a preparation for care programme combining a traditional habituation method with a digital immersive virtual reality tool ('PREPASOINS_VR'), compared with traditional habituation alone. In particular, the study aims to measure the impact of the use of IVR on the anxiety experienced during the actual treatment, as well as on various indicators relating to the delivery of the treatment, its progress and the experience of the patients.

02

Conditions studied

  • Psychological Disability
  • Mental Disability
03

In context

Lead sponsor

Pôle Saint Hélier is the lead sponsor of 23 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults:

    • Adults (age ≥ 18) at the time of enrollment
    • Users of the Handi Accès 35 program who have experienced treatment failure in mainstream healthcare settings
    • Individuals with a psychological or mental disability (e.g., autism spectrum disorders, Pervasive Developmental Disorder (PDD), Down syndrome, cerebral palsy, etc.) that creates significant barriers to accessing care (e.g., failure to receive care, failure due to past experience (perceived/contact-related), refusal of care, architectural barriers, anticipated failure, lack of external care options) documented in the medical record
    • Requiring a period of adjustment to care
    • Having given free and
    • Able to understand the French language (care acclimatization kits-available only in French)
    • Enrolled in a social security program or eligible for an equivalent benefit

Minors:

  • Children aged between 9 and 17 (inclusive) at the time of inclusion
  • Users of the Handi Accès 35 scheme who have been unable to access care in mainstream settings
  • People with a psychological or mental disability (for example: autism spectrum disorders, Pervasive Developmental Disorder (PDD), Down's syndrome, cerebral palsy, etc.) which creates significant barriers to accessing care (e.g. failure to access care, failure due to experience (perception/interaction), refusal of treatment, architectural barriers, anticipated failure, no external care provision) documented in the medical record
  • Requiring a period of adjustment to care
  • Registered with a social security scheme or entitled to an equivalent benefit
  • Able to understand French (care familiarisation kits - available in French only)
  • Minors for whom free, informed and written consent has been obtained from both holders of parental authority or, in exceptional cases, from a single holder under the conditions set out in Article L1122-2 of the Public Health Code.

Caregivers:

  • Adult: a person aged 18 or over
  • Informed consent: voluntary agreement to participate in the study following a full explanation of its terms.
  • Registered with a social security scheme or an eligible dependant
  • Agree to and be able to carry out the treatment familiarisation process with their relative and to accompany them to the dedicated consultation

Exclusion criteria

Exclusion Criteria:

  • majors : Participants requiring urgent medical care that prevents them from completing an 8-week familiarisation period with the treatment

    • Participants at high risk of epileptic seizures, or with uncontrolled epilepsy in the investigator's judgement, which contraindicates the use of VR.
    • Individuals with visual impairments that make the use of VR impossible
    • Individuals who refuse to wear the VR headset, in the investigator's judgement
    • Pregnant or breastfeeding women
    • Individuals deprived of their liberty by a judicial decision (excluding guardianship or curatorship) or an administrative decision.
    • Individuals in an emergency situation who are unable to give their prior consent.

minors : Individuals requiring urgent care that prevents them from completing an 8-week acclimatisation period

  • Refusal expressed by the child, notwithstanding the prior consent of the parents or holders of parental authority
  • Children subject to a court-ordered protection measure involving a specific placement, which is incompatible with participation in the study
  • A person presenting a major risk of epileptic seizures, or uncontrolled epilepsy in the investigator's judgement, which contraindicates the use of VR.
  • A person with visual impairments that make the use of VR impossible
  • A person refusing to wear the VR headset, in the investigator's judgement
  • Individuals deprived of their liberty by a judicial decision (excluding guardianship or curatorship) or an administrative decision.
  • Individuals in an emergency situation who are unable to give their prior consent.

Caregiver: Vulnerable individuals referred to in Articles L. 1121-5 to 8 and L. 1122-1-2 of the Public Health Code are excluded from the study:

  • Pregnant women, women in labour or breastfeeding women
  • Persons deprived of their liberty by a judicial decision (including guardianship, curatorship and judicial protection) or an administrative decision
  • Persons receiving psychiatric care or admitted to a health or social care facility for purposes other than research
  • Persons in an emergency situation who are unable to give their prior consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Traditional treatment habituation method only

    For each group, once they have been briefed, the following materials will be provided: * A monitoring kit and a logbook to support the user and monitor their adaptation to the treatment; * An information leaflet entitled 'Adapting to conventional treatment'; * A dummy wristband designed to help the user get used to wearing the 'Embrace Plus' wristband, which measures the level of anxiety.

    Behavioral: Traditional care habituation programme · Device: Embrace Plus wristband · Device: Dummy wristband

  • Experimental
    Traditional care habituation combined with virtual reality

    In addition to the traditional care habituation materials provided to participants in the control group, participants in this group will also receive: * A PREPASOINS\_VR immersive virtual reality familiarisation kit to prepare participants for upcoming medical and care procedures through immersive 360° videos; * An information leaflet explaining how to use the virtual reality familiarisation kit. The virtual reality programme includes eight care scenarios covering dental care, dental mobile unit visits, gynaecological and ophthalmological consultations, follow-up appointments for physical medicine and rehabilitation, somatic assessments, blood tests and electrocardiograms.

    Behavioral: Traditional care habituation programme · Device: Embrace Plus wristband · Device: PREPASOINS_VR virtual reality headset · Device: Dummy wristband

Interventions

  • BehavioralTraditional care habituation programme

    A traditional care habituation programme designed to familiarise participants with upcoming medical and care procedures. The programme uses conventional preparation materials and information to help participants understand and anticipate the different stages of the procedures. It aims to reduce anxiety associated with medical and care procedures. This intervention is provided to participants in both the control and experimental groups. In the experimental group, it is supplemented by an immersive virtual reality familiarisation programme (PREPASOINS\_VR).

  • DeviceEmbrace Plus wristband

    The Embrace Plus wristband is worn by participants in both study groups to monitor anxiety levels during the study. It is used as a monitoring device and does not deliver any therapeutic intervention.

  • DevicePREPASOINS_VR virtual reality headset

    An immersive virtual reality headset used with the PREPASOINS\_VR solution. The device enables participants to view immersive 360-degree videos presenting different medical and care scenarios as part of the care familiarisation programme. It is used exclusively in the experimental group.

  • DeviceDummy wristband

    A non-electronic dummy wristband used during the treatment habituation sessions to familiarise participants with wearing a wristband before the actual treatment procedure. The dummy wristband is used for habituation purposes only and does not record or monitor physiological parameters.

06

What researchers measure

Primary outcomes

  1. Skin Conductance (SC) During the Actual Treatment Procedure (µS)

    Skin conductance (SC), expressed in microsiemens (µS), measured using an Empatica wristband during the actual treatment procedure at Visit 1. Skin conductance reflects changes in the electrical conductance of the skin associated with sweat secretion by the eccrine sweat glands, particularly those located on the palms and soles. Skin conductance is a physiological measure of electrodermal activity (EDA) associated with sympathetic nervous system activity.

    Time frame: At Visit 1, during the actual treatment procedure (2-3 months after enrolment).

Secondary outcomes

  1. Change From Baseline in Caregiver-Reported Patient Anxiety Score on the Visual Analogue Scale at 2-3 Months

    Patient anxiety score as perceived and reported by the caregiver, measured using a Visual Analogue Scale (VAS) ranging from 0 to 10, where 0 indicates no anxiety and 10 indicates maximum anxiety. The assessment is performed at inclusion (baseline) and at Visit 1 (2-3 months after enrolment). The change in anxiety score between baseline and Visit 1 will be reported. Higher scores indicate higher levels of perceived anxiety (worse outcome).

    Time frame: At baseline (inclusion) and at Visit 1 (2-3 months after enrolment).

  2. Percentage of Care Provided During the Actual Treatment Procedure (%)

    The degree of care provision during the actual treatment procedure, assessed by the healthcare professional using a numerical scale ranging from 0% (care not provided) to 100% (care fully provided). Intermediate values indicate partial care provision. A derived categorical variable will also be reported, distinguishing complete care provision (100%) from incomplete care provision (partial care provision or no care provided).

    Time frame: Visit 1, during the actual treatment procedure (2-3 months after enrolment).

  3. Use of Premedication Before the Treatment Procedure (Yes/No)

    Use of premedication before the actual treatment procedure, recorded as a binary variable (yes/no). When premedication is used, its type (pharmacological or non-pharmacological) will also be recorded. For pharmacological premedication, the medication name and dose will be documented, when applicable.

    Time frame: At Visit 1 (between 2 and 3 months after enrolment).

  4. Use and Acceptance of Conscious Sedation With Nitrous Oxide/Oxygen (MEOPA)

    Use of conscious sedation with nitrous oxide/oxygen (MEOPA) during the actual treatment procedure, recorded as a categorical variable: administered and accepted, refused, or not used.

    Time frame: During the actual treatment procedure at Visit 1 (2-3 months after enrolment).

  5. Duration of Conscious Sedation With Nitrous Oxide/Oxygen (MEOPA) (Minutes)

    Duration of MEOPA administration during the actual treatment procedure, measured in minutes among participants who receive conscious sedation.

    Time frame: During the actual treatment procedure at Visit 1 (2-3 months after enrolment).

  6. Number of Preparatory Visits Before the Actual Treatment Procedure

    Number of preparatory visits ("dry runs") completed before the actual treatment procedure. A preparatory visit is defined as a visit during which the patient attends the treatment setting but the planned treatment is not performed. The total number of preparatory visits completed before the actual treatment will be recorded.

    Time frame: From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).

  7. Pain Score During the Treatment Procedure Measured Using the Postoperative Pain Assessment Grid for Individuals with Intellectual Disabilities (GED-DI)

    Pain experienced by the patient during the treatment procedure, measured using the Postoperative Version of the Pain Assessment Grid for Individuals with Intellectual Disabilities (Grille d'Évaluation de la Douleur - Déficience Intellectuelle, GED-DI). The scale consists of 27 behavioral items, each scored from 0 to 3, resulting in a total score ranging from 0 to 81. The scale is completed after the treatment by the healthcare professional who performed the procedure, with the assistance of a companion when necessary. Higher scores indicate greater pain intensity (worse outcome). Scores of 6-10 indicate mild pain, while scores of 11 or higher indicate moderate to severe pain.

    Time frame: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment)

  8. Caregiver Satisfaction With the Care Provided During the Treatment Procedure

    Caregiver satisfaction with the care provided during the actual treatment procedure, assessed using a 5-point Likert scale ranging from 1 (very dissatisfied) to 5 (very satisfied). The minimum score is 1 and the maximum score is 5. Higher scores indicate greater satisfaction and a better outcome. The questionnaire is completed by the caregiver, if present during the consultation.

    Time frame: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).

  9. Healthcare Professional-Rated Ease of Performing the Treatment Procedure

    The perceived ease of performing the actual treatment procedure, assessed by the healthcare professional using a 5-point Likert scale ranging from 1 (very difficult) to 5 (very easy). The minimum score is 1 and the maximum score is 5. Higher scores indicate greater ease of performing the procedure and a better outcome.

    Time frame: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).

  10. Duration of the Treatment Habituation Period (Days)

    Duration of the treatment habituation period, measured in days from the date of the first habituation session to the date of the actual treatment procedure. The duration is calculated as the number of calendar days between these two dates.

    Time frame: From the first habituation session until the actual treatment procedure at Visit 1 (2-3 months after enrolment).

  11. Number of Treatment Habituation Sessions

    Total number of habituation sessions completed by each participant between enrolment and the actual treatment procedure.

    Time frame: From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).

  12. Recruitment Rate (%)

    Proportion of eligible participants who agreed to participate and were enrolled in the study, calculated as the number of enrolled participants divided by the number of eligible participants approached, multiplied by 100.

    Time frame: From the start of recruitment until the end of the recruitment period, up to 12 months

  13. Recruitment Speed (Participants per Month)

    Average number of participants enrolled per month during the recruitment period, calculated as the total number of enrolled participants divided by the number of months of active recruitment.

    Time frame: Up to 12 months

  14. Eligibility Rate (%)

    Proportion of individuals assessed for eligibility who met all study eligibility criteria, calculated as the number of eligible individuals divided by the total number of individuals assessed for eligibility, multiplied by 100.

    Time frame: Up to 12 months

  15. participant Refusal Rate (%)

    Proportion of individuals approached for study participation who declined to participate, calculated as the number of individuals who refused participation divided by the total number of individuals approached, multiplied by 100.

    Time frame: Up to 12 months

  16. Intervention Adherence Rate (%)

    Proportion of enrolled participants who completed at least two treatment habituation sessions, calculated as the number of participants completing at least two sessions divided by the total number of enrolled participants, multiplied by 100.

    Time frame: From enrolment up to Visit 1, up to 3 months

  17. Acceptance Rate of the Dummy Wristband (%)

    Proportion of participants who accepted wearing the dummy wristband, calculated as the number of participants who accepted wearing the dummy wristband divided by the total number of participants offered the dummy wristband, multiplied by 100.

    Time frame: During the habituation period prior to Visit 1, up to 3 months post-enrolment

  18. Acceptance Rate of the Embrace Plus Wristband on the Treatment Day (%)

    Proportion of participants who accepted wearing the Embrace Plus wristband during the actual treatment procedure, calculated as the number of participants who accepted wearing the wristband divided by the total number of participants offered the wristband, multiplied by 100.

    Time frame: At Visit 1, up to 3 months post-enrolment

  19. Main Reasons for Non-Participation

    Main reasons reported by individuals who declined participation in the study, recorded as categorical data.

    Time frame: Up to 12 months

  20. Time Interval Between Initial Contact and Study Inclusion (Days)

    Time interval, measured in calendar days, between the date of initial contact with the potential participant and the date of study inclusion.

    Time frame: From initial contact until study inclusion, up to 12 months

  21. Participant Follow-up Completion Rate (%)

    Proportion of enrolled participants who completed the planned study follow-up assessment at Visit 1, calculated as the number of participants completing Visit 1 divided by the total number of enrolled participants, multiplied by 100

    Time frame: From enrolment until Visit 1 (2-3 months after enrolment).

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Mar 2028, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Mar 30, 2028
CompletionEst.
Mar 30, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07949097
Lead sponsor
Pôle Saint Hélier
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Mar 30, 2028 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Aurélie Dr DURUFLE, Principal Investigator
Contact
aurelie.durufle@fondationsainthelier.com
+33299295099

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion